tiprankstipranks
Seagen downgraded to Equal Weight from Overweight at Morgan Stanley
The Fly

Seagen downgraded to Equal Weight from Overweight at Morgan Stanley

Morgan Stanley analyst Matthew Harrison downgraded Seagen (SGEN) to Equal Weight from Overweight with a price target of $229, up from $173, after Pfizer (PFE) announced an agreement to acquire Seagen for $229 per share for a total amount of $43B. The analyst expects the deal to be completed by the end of 2023 or early 2024. There is minimum overlap between Pfizer’s current pipeline and Seagen’s platform, the analyst tells investors in a research note.

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on SGEN:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles